Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and that a trial for a different form of MS didn’t succeed.
Source: MarketWatch
Monday, 15. December 2025
Share:
15. December 2025 10:43
Sanofi stock slumps after two setbacks on multiple-sclerosis drug
